Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raphamin for Acute Respiratory Viral Infection
NCT04244084Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Oct 2019
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory viral infection (ARVI) comparing MMH-407 with Placebo (2 arms). Primary endpoint: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms at 14 days. Started Oct 2019; status: completed.
02
Drugs
raphamin
03
Conditions
acute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT04244084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244084.